Trials / Completed
CompletedNCT00434317
Assessment of Pain and Quality of Life in Breast and Prostate Cancer Patients With Bone Metastases
A Multicenter, Open-label Study to Determine the Effect of iv. Zoledronic Acid on Pain and Quality of Life in Patients With Bone Metastases With or Without Skeletal Related Events (SRE) Resulting From Breast Cancer and Prostate Cancer
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 80 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety, tolerability and efficacy of zoledronic acid administered intravenously every 3-4 weeks in patients with bone metastases from either breast cancer or prostate cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zoledronic acid |
Timeline
- Start date
- 2005-08-01
- Primary completion
- 2008-04-01
- First posted
- 2007-02-13
- Last updated
- 2017-02-23
Locations
4 sites across 1 country: Hungary
Source: ClinicalTrials.gov record NCT00434317. Inclusion in this directory is not an endorsement.